218 related articles for article (PubMed ID: 18398734)
1. Novel anti-myeloma agents and angiogenesis.
Anargyrou K; Dimopoulos MA; Sezer O; Terpos E
Leuk Lymphoma; 2008 Apr; 49(4):677-89. PubMed ID: 18398734
[TBL] [Abstract][Full Text] [Related]
2. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
[TBL] [Abstract][Full Text] [Related]
3. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
5. [The plasma cell myeloma--molecular pathogenesis and target therapies].
Hess U
Ther Umsch; 2006 Apr; 63(4):233-6. PubMed ID: 16689452
[TBL] [Abstract][Full Text] [Related]
6. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
Rajkumar SV; Witzig TE
Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
[TBL] [Abstract][Full Text] [Related]
8. Current treatment landscape for relapsed and/or refractory multiple myeloma.
Dimopoulos MA; Richardson PG; Moreau P; Anderson KC
Nat Rev Clin Oncol; 2015 Jan; 12(1):42-54. PubMed ID: 25421279
[TBL] [Abstract][Full Text] [Related]
9. Novel biologically based therapies for myeloma.
Anderson KC
Cancer J; 2001; 7 Suppl 1():S19-23. PubMed ID: 11504280
[TBL] [Abstract][Full Text] [Related]
10. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Highsmith KN; Chen SE; Horowitz S
Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
Raje N; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide in multiple myeloma.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors and modulators of angiogenesis in multiple myeloma.
Ferrarini M; Ferrero E
Curr Med Chem; 2011; 18(34):5185-95. PubMed ID: 22087819
[TBL] [Abstract][Full Text] [Related]
15. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
16. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.
Bianchi G; Ghobrial IM
Leuk Lymphoma; 2013 Feb; 54(2):229-41. PubMed ID: 22897729
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Ghobrial J; Ghobrial IM; Mitsiades C; Leleu X; Hatjiharissi E; Moreau AS; Roccaro A; Schlossman R; Hideshima T; Anderson KC; Richardson P
Oncology (Williston Park); 2007 Jun; 21(7):785-92; discussion 798-800. PubMed ID: 17722741
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
Berenson A; Vardanyan S; David M; Wang J; Harutyunyan NM; Gottlieb J; Halleluyan R; Spektor TM; Udd KA; Eshaghian S; Nassir Y; Eades B; Swift R; Berenson JR
Ann Hematol; 2017 Mar; 96(3):449-459. PubMed ID: 27933373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]